{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"151","upperLimit":"257","value":"205"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"description":"Overall survival was calculated from the date of the first treatment until death of the subject.\n\nEvaluation by Kaplan-Meier methodology, descriptive analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (bid, bis in die) X 28 day cycles","id":"OG000","title":"Sorafenib"}],"paramType":"MEDIAN","populationDescription":"The analysis population for the intent to treat (ITT) and safety analyses consisted of 52 subjects who received at least 1 treatment and had their disease re-evaluated. 51 subjects were considered evaluable since 1 of the 52 subjects had lung metastases from pancreatic cancer.","reportingStatus":"POSTED","timeFrame":"First patient first treatment until date for last data collection for efficacy for a study period up to 62 weeks.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"days"}